Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Beth A. Christian"'
Autor:
Walter Hanel, Polina Shindiapina, David A. Bond, Yazeed Sawalha, Narendranath Epperla, Timothy Voorhees, Rina Li Welkie, Ying Huang, Gregory K. Behbehani, Xiaoli Zhang, Eric McLaughlin, Wing K. Chan, Jonathan E. Brammer, Samantha Jaglowski, John C. Reneau, Beth A. Christian, Basem M. William, Jonathon B. Cohen, Robert A. Baiocchi, Kami Maddocks, Kristie A. Blum, Lapo Alinari
Publikováno v:
Cancers, Vol 15, Iss 5, p 1437 (2023)
Background: Relapsed or refractory classical Hodgkin lymphoma (cHL) remains a difficult treatment challenge. Although checkpoint inhibitors (CPI) have provided clinical benefit for these patients, responses are generally not durable, and progression
Externí odkaz:
https://doaj.org/article/d6ef23914235448d9484ea9296f388ca
Autor:
David A. Bond, Ying Huang, Beth A. Christian, Samantha Jaglowski, Don Benson, Lapo Alinari, Robert A. Baiocchi, Jonathon B. Cohen, Kristie A. Blum, Kami J. Maddocks
Publikováno v:
Leukemia & Lymphoma. 63:1750-1753
Autor:
Lisa Brown, Ann S. LaCasce, Linda Ho, Beth A. Christian, Chiyu Zhang, Nancy L. Bartlett, Ranjana H. Advani, Alex F. Herrera, Sahar Ansari, David R. Taft, Mariana Sacchi, Tatyana Feldman, Alison J. Moskowitz, Stephen M. Ansell, Julie M. Vose, Craig H. Moskowitz, Radhakrishnan Ramchandren
Publikováno v:
Blood. 138(6)
This phase 1-2 study evaluated brentuximab vedotin (BV) combined with nivolumab (Nivo) as first salvage therapy in patients with relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). In parts 1 and 2, patients received staggered dosing of BV an
Autor:
Arwa Shana'ah, Beth A. Christian, Jennifer A. Woyach, Kami J. Maddocks, Dan Jones, Narendranath Epperla, Sabarish Ayyappan
Publikováno v:
Blood Advances. 3:500-502
Ibrutinib is approved by the US Food and Drug Administration for the treatment of patients with relapsed/refractory marginal zone lymphoma (MZL) who are progressing on at least 1 previous anti-CD20–based therapy. This approval was based on the resu
Autor:
Kimberly Davies, Michael E. Williams, William Martin-Doyle, Jakub Svoboda, Zhengming Chen, Beth A. Christian, Catherine M. Bollard, Ann S. LaCasce, James Godfrey, Matthew J. Barth, Rebecca Gardner, Jody Sima, Matthew J. Oberley, Kristie A. Blum, Amanda M. Termuhlen, John P. Leonard, Tara O'Donohue, Sheila Weitzman, Zeinab Afify, Burton Appel, Christopher J. Forlenza, Hema Dave, Jennifer Levine, Carla Casulo, Deborah M. Stephens, Benjamin Mizukawa, Nancy L. Bartlett, Sonali M. Smith, Melinda Pauly, Sarah Alexander, Lisa Giulino-Roth, William A. Zeitler
Publikováno v:
British Journal of Haematology. 179:739-747
Summary Treatment with dose-adjusted EPOCH (etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone) chemotherapy and rituximab (DA-EPOCH-R) has become the standard of care for primary mediastinal B-cell lymphoma (PMBCL) at many institution
Autor:
Todd A. Fehniger, Steven M. Devine, Samantha Jaglowski, Nancy L. Bartlett, Lai Wei, Mitch A. Phelps, Beth A. Christian, Xiaohua Zhu, Jennifer Sexton, Joseph Maly, Nina D. Wagner-Johnston, Kristie A. Blum
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 17:347-353
Background Lenalidomide and panobinostat have shown single-agent efficacy of 14% to 50% and 27% to 58%, respectively, in Hodgkin lymphoma (HL). This phase I/II study was conducted to determine the maximum tolerated dose (MTD), safety, and efficacy of
Autor:
Ming Poi, Wenjun Ni, Flavia Pichiorri, Mitch A. Phelps, Jiang Wang, Douglas W. Sborov, Don M. Benson, Pierluigi Porcu, Craig C. Hofmeister, Joseph M. Flynn, Robert A. Baiocchi, Erinn M. Hade, Amir Mortazavi, Christopher C. Coss, Soun Khountham, Alessandro Canella, John C. Byrd, Xiaokui Mo, Leslie A. Andritsos, Beth A. Christian, Zhongfa Liu
Publikováno v:
Leukemia & Lymphoma. 58:2310-2318
Histone deacetylase inhibitors (HDACi) have proven activity in hematologic malignancies, and their FDA approval in multiple myeloma (MM) and T-cell lymphoma highlights the need for further development of this drug class. We investigated AR-42, an ora
Autor:
Arwa Shana'ah, Abner Louissaint, Berkman Sahiner, Robert P. Hasserjian, Beth A. Christian, Weijie Chen, Gerard Lozanski, Muhammad Khalid Khan Niazi, Metin N. Gurcan, Fazly Salleh Abas, Michael L. Pennell
Publikováno v:
Cytometry Part A. 91:609-621
The advance of high resolution digital scans of pathology slides allowed development of computer based image analysis algorithms that may help pathologists in IHC stains quantification. While very promising, these methods require further refinement b
Autor:
Beth A. Christian, Ying Huang, Sabarish Ayyappan, Robert A Baiocchi, Jonathan E Brammer, Narendranath Epperla, Samantha Jaglowski, Basem M. William, Farrukh T. Awan, Kami J. Maddocks, Kristie A. Blum
Publikováno v:
Blood. 134:4082-4082
Introduction: Venetoclax, a BCL2 inhibitor, has demonstrated efficacy both as a single agent and in combination with rituximabin several subtypes of B-cell non-Hodgkin lymphoma (NHL). The combination of obinutuzumab and lenalidomide has demonstrated
Autor:
David W. Taft, Tatyana Feldman, Alex F. Herrera, Beth A. Christian, Mariana Sacchi, Julie M. Vose, Thomas Manley, Ann S. LaCasce, Stephen M. Ansell, Craig H. Moskowitz, Alison J. Moskowitz, Sahar Ansari, Daniel E. Zak, Lisa Brown, Radhakrishnan Ramchandren, Ranjana H. Advani, Nancy L. Bartlett
Publikováno v:
Blood. 134:238-238
Introduction Brentuximab vedotin (BV) targets CD30, a receptor expressed on the Reed-Sternberg cells of classic Hodgkin lymphoma (cHL). Nivolumab (Nivo) restores antitumor immunity by blocking the PD-1 receptor on activated T-cells. In this phase 1/2